Stock listing

Ono Pharmaceutical Co., Ltd.

Selected listing: ON40 · MUN · EUR · DE

Ono Pharmaceutical Co., Ltd. (Munich:ON40), Health Technology. Latest release Sep 16, 2026: Ono Pharmaceutical : Received Manufacturing and Marketing Approval…

ON40:MUNEURDEUpdated September 26, 2026

Ticker: Munich:ON40
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Munich
Currency: EUR

Latest news from Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical : Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures

September 16, 2026

KANEKA UBIQUINOL™ MEMENANGI NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026

September 8, 2026

Ono Pharmaceutical : OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO

August 19, 2026

Ono Pharmaceutical : Continues to be Selected for ESG Investment Indexes Adopted by GPIF

August 17, 2026

Ono Pharmaceutical : OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO

August 4, 2026

All Ono Pharmaceutical Co., Ltd. news →

Research Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd. company profile

View the public company page for Ono Pharmaceutical Co., Ltd. on 6ix.

Ono Pharmaceutical Co., Ltd. news

Read company news and market updates connected to Ono Pharmaceutical Co., Ltd..

Ono Pharmaceutical Co., Ltd. investor events

Find investor webinars, events, and replay context for Ono Pharmaceutical Co., Ltd..